SAN DIEGO, Feb. 7, 2024 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its new analytical platform, LabZient™. The standardized and automated platform streamlines the assessment and validation of large molecules, which significantly reduces drug development timelines and resource costs.
SAN DIEGO, Dec. 19, 2023 /PRNewswire/ -- Abzena, the leading end-to-end CDMO for complex biologics and bioconjugates, has co-authored a publication with the US Food and Drug Administration (FDA) demonstrating the potential of the MHC Associated Peptide Proteomics (MAPPs) assay as an important method to interrogate immunogenicity risk and help design superior antibody and biologics with a higher chance of a successful outcome in patients.
Abzena, a CDMO for complex biologics and antibody drug conjugates (ADCs), has appointed Thomas Castellano, Chief Financial Officer.
Abzena, an integrated contract development and manufacturing organization (CDMO) for complex biologic molecules and antibody drug conjugates (ADCs), has appointed Sean O’Brien as senior vice president and site head at its San Diego manufacturing facility.
Abzena, an integrated contract development and manufacturing organization (CDMO) for antibody drug conjugates (ADCs) and complex biologic molecules, strengthened its senior leadership team with the appointment of Joe Principe as chief commercial officer, and Matthew Pinkston as vice president, program management.
Abzena, a CDMO specializing in the development and manufacture of antibody-drug conjugates, has laid off 66 employees in San Diego, according to a Worker Adjustment and Retraining Notification (WARN) posted by the state.
Pfizer inks deal to snatch Abzena`s new North Carolina manufacturing site
Abzena, an end-to-end integrated contract development and manufacturing organization (CDMO) for antibody drug conjugates (ADCs) and complex biologic molecules, has appointed Matthew Stober as their new CEO.
Abzena Bulks up R&D Services to Include B Cell Discovery Tech
Abzena, a provider of integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), is opening of a new biologics testing laboratory situated in close proximity to its biologics process development and manufacturing hub in San Diego, CA. This brand-new facility will give Abzena’s partners access to cell-based and PCR safety assays; and viral clearance studies to support their IND, IMPD, BLA and MAA applications.